Buy Dexilant

Dexilant

Dexilant: Generic Medication Overview

Dexilant contains the active ingredient dexlansoprazole, a proton-pump inhibitor (PPI) used to treat conditions related to excess stomach acid. It is available as a pill in strengths of 30 mg and 60 mg. In Hong Kong, Dexilant is a prescription-only medication regulated by the Department of Health.

How Dexilant Works in the Body

Dexlansoprazole belongs to the PPI class, which suppresses gastric acid production by irreversibly blocking the H⁺/K⁺-ATPase enzyme (the “proton pump”) located on the parietal cells of the stomach lining. By inhibiting this final step in acid secretion, Dexilant reduces both basal and stimulated gastric acidity.

• Onset of action: Acid suppression begins within 1 hour after the first dose.
• Peak effect: Maximal inhibition is typically reached after 4 hours.
• Duration: The drug’s effect can last up to 24 hours because new proton pumps must be synthesized for acid production to resume.

Dexlansoprazole has a dual delayed-release formulation, allowing two separate releases of the drug in the gastrointestinal tract. This design extends the period of acid suppression compared with some other PPIs, helping to maintain a higher gastric pH throughout the day.

Conditions Treated by Dexilant

Dexilant is approved in many jurisdictions, including Hong Kong, for the following indications:

• Erosive esophagitis (damage to the esophagus caused by stomach acid).
• Gastro-oesophageal reflux disease (GERD) with persistent symptoms despite once-daily PPI therapy.
• Maintenance of healed erosive esophagitis to prevent relapse.

Typical patients are adults who experience heartburn, acid regurgitation, or discomfort caused by acid exposure to the esophageal lining. Dexilant is not indicated for pediatric use unless specifically prescribed by a specialist.

Evidence-Based Off-Label Uses

• Helicobacter pylori eradication regimens sometimes include a PPI to improve antibiotic efficacy. Dexilant can be used as part of a triple or quadruple therapy, but it is not the preferred or approved agent for this purpose.
• Prevention of NSAID-induced gastric ulcers may be considered in high-risk patients. This use is off-label and should be guided by a gastroenterologist.

Off-label use requires medical supervision and individualized risk assessment.

Who Should (Not) Use Dexilant?

Absolute Contraindications

• Known hypersensitivity to dexlansoprazole, any other PPI, or any component of the tablet.

Relative Contraindications

• Severe liver disease (e.g., Child-Pugh class C).
• Concomitant use of drugs that require an acidic environment for absorption (e.g., ketoconazole, atazanavir) unless dosage adjustments are made.

Special Populations

• Pregnancy: Dexilant is classified as Category B (animal studies show no risk; no adequate human studies). Use only if the potential benefit outweighs the risk.
• Lactation: Small amounts are excreted in breast milk; a decision to breastfeed while on Dexilant should be made with a healthcare professional.
• Elderly: Dose adjustment is not routinely required, but renal or hepatic impairment should be evaluated.

If you have any of the above conditions, discuss alternatives with your prescriber.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Headache - often mild and transient.
• Diarrhea or constipation - usually resolves after a few days.
• Upper abdominal pain - can be relieved by taking the medication with food.
• Nausea - may improve by swallowing the tablet with a full glass of water.

Serious Adverse Events

• Clostridioides difficile infection - rare but potentially severe; seek medical attention for persistent watery diarrhea.
• Bone fracture risk - long-term PPI use has been associated with decreased calcium absorption; discuss bone health monitoring if therapy exceeds one year.
• Vitamin B12 deficiency - prolonged suppression of stomach acid can impair B12 absorption; periodic testing may be advised.

Drug Interactions

• Major: Concomitant use of clopidogrel may reduce its antiplatelet effect; consider alternative antiplatelet agents.
• Moderate: Antifungals (e.g., ketoconazole, itraconazole) and protease inhibitors (e.g., atazanavir) require dose adjustments because reduced acidity impairs their absorption.
• CYP2C19 inhibitors (e.g., fluvoxamine, omeprazole) can increase dexlansoprazole plasma levels; monitor for increased side effects.
• CYP2C19 inducers (e.g., rifampin, carbamazepine) may lower dexlansoprazole exposure, potentially reducing efficacy.

Food and Lifestyle Interactions

• Dexilant can be taken with or without food; however, consistent timing improves symptom control.
• Alcohol does not directly interact, but excessive intake may exacerbate GERD symptoms.
• Driving or operating machinery is not impaired by the medication.

Patients should disclose all prescription drugs, OTC products, supplements, and herbal remedies to their healthcare provider before starting Dexilant.

How to Take Dexilant

• Standard dosing:
• For erosive esophagitis, the usual adult dose is 30 mg once daily for up to 8 weeks.
• For maintenance of healed esophagitis, 30 mg once daily is typical; some clinicians may prescribe 60 mg once daily for patients with persistent symptoms.
• Administration: Swallow the pill whole with a full glass of water. Do not crush, chew, or split the tablet.
• Special populations:
• Renal impairment: No dosage change is required for mild to moderate renal dysfunction, but severe impairment should be evaluated by a physician.
• Hepatic impairment: Start with 30 mg; dose may be reduced in severe liver disease.
• Missed dose: Take the missed dose as soon as remembered, unless it is close to the time of the next scheduled dose. Do not double the dose.
• Overdose: Symptoms may include severe abdominal pain, nausea, or vomiting. Seek emergency medical care; treatment is supportive, and there is no specific antidote.
• Discontinuation: Dexilant can be stopped abruptly, but patients experiencing rebound acid hypersecretion may benefit from a tapered reduction under medical guidance.

Monitoring and Follow-Up

• Symptom assessment: Re-evaluation after 4-8 weeks of therapy to determine healing of esophageal lesions.
• Laboratory tests: For long-term users, consider periodic monitoring of serum magnesium, calcium, and vitamin B12 levels.
• Bone health: In patients with risk factors for osteoporosis, a bone density scan may be advised after several years of continuous use.

Regular follow-up with a gastroenterologist or primary care provider ensures optimal symptom control and early detection of potential complications.

Storage and Handling

• Store Dexilant tablets at room temperature (15 °C - 30 °C), away from moisture and direct sunlight.
• Keep the container tightly closed and out of reach of children.
• Do not use the medication after the expiration date printed on the package.
• Dispose of unused tablets according to local pharmacy take-back programs or the instructions on the package label.

Medication-Specific Glossary

Proton-Pump Inhibitor (PPI)

A class of drugs that irreversibly blocks the gastric H⁺/K⁺-ATPase enzyme, reducing stomach acid production.

CYP2C19

A liver enzyme that metabolizes many medications, including dexlansoprazole; genetic variability can affect drug levels.

Erosive Esophagitis

Inflammation and ulceration of the esophageal lining caused by chronic exposure to gastric acid.

Bioavailability

The proportion of an orally administered drug that reaches systemic circulation unchanged.

Rebound Acid Hypersecretion

Increased gastric acid output that can occur after abrupt discontinuation of a PPI.

Medical Disclaimer

This article provides educational information about Dexilant and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.